Penicillin break: major trial tests if kids with mild RHD can ditch daily antibiotics
NCT ID NCT07146048
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 3 trial will test whether children and teens with mild rheumatic heart disease (RHD) can safely stop taking long-term penicillin. About 922 participants aged 5-20 who have stable or normalized RHD after at least 2 years of antibiotics will be randomly assigned to either continue or stop penicillin. Researchers will track if their heart condition gets worse over 2 years using echocardiograms.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
penicillin (antibiotic prophylaxis)
What this could lead to
If successful, this could show that some children with mild rheumatic heart disease can safely stop long-term penicillin without their heart condition getting worse.
What could go wrong
This is a non-inferiority trial, so it is designed to show that stopping is not worse than continuing. Even if it succeeds, the results may only apply to children with very mild or normalized disease, and longer follow-up may reveal risks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RHEUMATIC HEART DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Uganda Heart Institute
RECRUITINGKampala, UG, Uganda
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••